title: Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma.
abstract: Fourteen patients with diffuse malignant pleural mesothelioma (DMPM) were enrolled in a Phase II study to assess activity and toxicity of the systemic administration of recombinant (r)-alpha-interferon (IFN)-2b. The IFN schedule was: 3 x 10(6) IU i.m. days 1-4, 6 x 10(6) IU days 5-8, 10 x 10(6) IU days 9-12; then IFN was administered at 10 x 10(6) IU 3 days/week. If grades II-III toxicity occurred, IFN dose was reduced and drug continued at the previous dose level. All patients were evaluated by CT scan. Only one patient was not evaluable for response and toxicity because of inadequate follow-up. Of 13 evaluable patients, we observed 1 objective response, 6 stable disease, and 6 failures (3 progressive disease and 3 early interruptions due to subjective toxicity). The median time to progression was 19 weeks, and the median overall survival was 62 weeks. Toxicity was mild: of 13 patients evaluable for toxicity we observed fever (9 patients), flu-like syndrome (3 patients), fatigue (4 patients), anorexia (2 patients), myelosuppression (3 patients), and muscle pain (1 patient). The results of this study indicate only marginal activity of r-alpha-IFN in the treatment of DMPM.
authors.affiliation: Department of Medical Oncology, Ospedale S. Spirito of Casale Monferrato, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Ardizzoni
authors.forename: M C
authors.initials: MC
authors.lastname: Pennucci
authors.forename: B
authors.initials: B
authors.lastname: Castagneto
authors.forename: G L
authors.initials: GL
authors.lastname: Mariani
authors.forename: A
authors.initials: A
authors.lastname: Cinquegrana
authors.forename: D
authors.initials: D
authors.lastname: Magri
authors.forename: A
authors.initials: A
authors.lastname: Verna
authors.forename: F
authors.initials: F
authors.lastname: Salvati
authors.forename: R
authors.initials: R
authors.lastname: Rosso
mesh_terms: D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins